Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines

CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ — Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus Bio, pairing their technologies to resolve challenges related to the delivery of complex genetic materials to living human cells. “Gene-modified cell therapies hold great promise for patients. […]
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts

San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy. The newly formed SAB will provide input into […]
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board

SAN DIEGO, July 26, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida’s newly formed Gene Therapy Scientific Advisory […]
ALDEVRON LICENSES THE MANUFACTURING OF A TYPE-V CRISPR NUCLEASE FROM INSCRIPTA

FARGO, N.D. , May 16, 2022 /PRNewswire/ —Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron […]